3.4.22.B30: calpain 10

This is an abbreviated version!
For detailed information about calpain 10, go to the full flat file.

Word Map on EC 3.4.22.B30

3.4.22.B30

calpains

mellitus

ucsnp-43

polycystic

tcf7l2

mexican

kcnj11

medicine

mexican-american

pro12ala

7-like

igf2bp2

haplogenotype

cdkal1

drug development

Reaction

broad endopeptidase specificity =

Synonyms

calpain 10, calpain-10, CAPN10

ECTree

3 Hydrolases

3.4 Acting on peptide bonds (peptidases)

3.4.22 Cysteine endopeptidases

3.4.22.B30 calpain 10

Advanced search results

Do not include text mining results

Include

results (more...)

Include

results (more...)

Results	in table
6	Activating Compound
4	AA Sequence
15	Application
1	CAS Registry Number
7	Cloned(Commentary)
991	Disease/ Diagnostics
5	Expression
16	General Information
3	IC50 Value
17	Inhibitors
23	Localization
11	Metals/Ions
10	Molecular Weight [Da]
16	Natural Substrates/ Products (Substrates)
55	Organism
7	Protein Variants
2	Purification (Commentary)
1	Reaction
2	Reaction Type
54	Reference
58	Source Tissue
37	Substrates and Products (Substrate)
8	Subunits
35	Synonyms

Activating Compound

print visible entries

print all entries

Go back to the abbreviated version
of the Enzyme Summary Page.

Activating Compound on EC 3.4.22.B30 - calpain 10

Please wait a moment until all data is loaded. This message will disappear when all data is loaded.

top print hide

Go to Activating Compound Search

angiotensin II

Homo sapiens

Q9HC96

activates the enzyme in vivo, reduced by pan-calpain inhibitors

Ca2+

glucose

gradual increase after 3.5 days of exposure

666361

intralipid

Homo sapiens

Q9HC96

fat emulsion consisting of 12% palmitic acid, 4% stearic acid, 21% oleic acid, 53% linoleic acid, 7% alpha-linoleic acid, and 3% other acids, after 24 h exposure, increase in CAPN10 mRNA in response to insulin in subjects with normal glucose tolerance

664717